Mark Rosenberg, Author at AskBio

AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF) Posted on January 5, 2024 (January 5, 2024) by Mark Rosenberg in News
AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions Posted on November 12, 2023 (November 13, 2023) by Mark Rosenberg in News
AskBio Contribution to Advancing Gene Therapy Highlighted at ESGCT 30th Congress Posted on October 23, 2023 (October 23, 2023) by Mark Rosenberg in News
AskBio Announces 11 Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting in 2023 Posted on May 11, 2023 (May 11, 2023) by Mark Rosenberg in News
AskBio to Present Phase 1b Results Investigating AB-1005 (formerly AAV2-GDNF) as Treatment for Parkinson’s Disease at AD/PD^TM 2023 International Conference on Alzheimer’s and Parkinson’s Diseases Posted on March 29, 2023 (March 29, 2023) by Mark Rosenberg in News
AskBio Announces Gustavo Pesquin as New CEO Posted on March 9, 2023 (March 9, 2023) by Mark Rosenberg in News
AskBio Receives European Commission Orphan Drug Designation through its EU-Based subsidiary BrainVectis for AB-1003, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy (LGMD) Posted on February 27, 2023 (February 27, 2023) by Mark Rosenberg in News&Uncategorized
AskBio Co-Founder R. Jude Samulski and Team of AskBio Scientists Author Paper Published in Prestigious Journal Posted on January 26, 2023 (January 26, 2023) by Mark Rosenberg in News
AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform Posted on January 9, 2023 (January 9, 2023) by Mark Rosenberg in News
Recombinant Adeno-Associated Virus (rAAV) Technology
Pioneered by AskBio’s Dr. Jude Samulski is Key Component
of All FDA Approved AAV Gene Therapeutics Posted on December 19, 2022 (December 20, 2022) by Mark Rosenberg in News